Latest Breaking News On - Targeted augmentation - Page 9 : comparemela.com

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

– Company on-track to report new data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents with Dravet syndrome in mid-2023 – – Data readout will focus on safety and seizure frequency results for up to 16 patients who received three doses of 45mg of STK-001 –– Company plans to initiate.

United kingdomUnited statesEric rojasEdwardm kayeExchange commissionStoke therapeutics incAugmentation of nuclear gene output is stokeAugmentation of nuclear gene outputCompany annual report on formRegulatory agencyAutosomal dominant optic atrophyStoke therapeuticsChief executive officerClinical trial applicationUnited kingdom medicinesCollaboration agreement

Stoke Therapeutics, Inc : Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom

- Company advancing second TANGO ASO into the clinic - - STK-002 has the potential to be the first disease-modifying therapy to address the root cause of ADOA, the most common inherited optic nerve

United kingdomUnited statesBarry tichoEric rojasCompany annual report on formAugmentation of nuclear gene outputRegulatory agencyAugmentation of nuclear gene output is stokeExchange commissionStoke therapeutics incClinical trial applicationUnited kingdom medicinesChief medical officerAutosomal dominant optic atrophyTargeted augmentationNuclear gene output

Stoke Therapeutics Inc (STOK) Receives Authorization to Initiate a Phase 1/2 Study of STK-002

Stoke Therapeutics Inc (STOK) Receives Authorization to Initiate a Phase 1/2 Study of STK-002
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomBarry tichoEric rojasAugmentation of nuclear gene outputRegulatory agencyAugmentation of nuclear gene output is stokeExchange commissionCompany annual report on formStoke therapeutics incWall streetClinical trial applicationUnited kingdom medicinesChief medical officerAutosomal dominant optic atrophyTargeted augmentation

Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom

Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesBorough of bedfordEric rojasBarry tichoAugmentation of nuclear gene outputRegulatory agencyExchange commissionCompany annual report on formAugmentation of nuclear gene output is stokeStoke therapeutics incClinical trial applicationUnited kingdom medicinesChief medical officerAutosomal dominant optic atrophyTargeted augmentation

Stoke Therapeutics : Dosing anticipated to start in the coming weeks - - Company remains on track for its planned data readouts from the Phase 1/2a MONARCH and ADMIRAL studies in 2023 - Form 8-K

- Dosing anticipated to start in the coming weeks - - Company remains on track for its planned data readouts from the Phase 1/2a MONARCH and ADMIRAL studies in. | March 15, 2023

United statesUnited kingdomBorough of bedfordBarry tichoAugmentation of nuclear gene output is stokeAugmentation of nuclear gene outputStoke therapeutics incChief medical officerTargeted augmentationNuclear gene outputStoke therapeuticsNc stock exchangePress releaseTudies stok us86150r1077